S. Korea's Kwan Dong Says OAB Drug Shown Successful In Phase II Trials
This article was originally published in PharmAsia News
Executive Summary
Kwan Dong Pharmaceutical of South Korea and Laboratorios Salvat of Spain announced success in a Phase II trial of tarafenacin as a treatment for overactive bladder syndrome.